Oct 24,2023 TOP STORY

Signos Announces Series B Funding Round of $20 Million

Signos, a metabolic health platform that utilizes a unique AI-engine with a continuous glucose monitor (CGM) to offer real-time data and recommendations for healthy weight management, has announced a successful $20 million Series B funding round. The round was led by Cheyenne Ventures and GV (Google Ventures), with additional investments from Dexcom Ventures and Samsung. It will enable Signos to expand its team, extend its platform and conduct further research on metabolic health. The Signos app allows users to log their food intake and exercise levels, enabling the AI platform to learn how an individual’s metabolism responds to various foods and fitness patterns. This information then provides personalized, data-driven recommendations based on an individual’s unique metabolic profile.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Oct 03,2023

Journeys Metabolic unveils the first enterprise intervention platform for improving metabolic health at scale

Journeys Metabolic, an enterprise intervention platform that helps value-based organizations improve clinical and financial outcomes for metabolic disease, announced today the availability of its novel digital solution. The Journeys Metabolic HI-TRUST, EHR-interoperable platform enables clinical and financial decision-makers, including care management teams, to standardize metabolic care for their population health initiatives via an automated provider workflow engaging qualified, targeted patient populations. The core clinical component of the platform is a 4-month, physician-developed, digital program that drives long-term behavior modification to support the reversal and prevention of metabolic disease initiatives for patients with type 2 diabetes, NAFLD, metabolic syndrome, and obesity. The program will leverage AI-driven behavioral archetyping and diagnostic profiling to provide a personalized, precision-guided nutritional experience.

PRODUCT

#virtual care

View Analyst & Ambassador Comments
Go to original news